ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
Physical activity is a growing priority for patients with MS
Recent research suggests that exercise may benefit patients with MS.
Conference Coverage
New digital tools hold promise for patients with MS
High-tech tools currently in development can detect not only motor and visual dysfunction but also cognitive dysfunction.
Conference Coverage
MS looks homogeneous
An analysis of clinical factors and treatment responses calls for personal rather than precision medicine.
Conference Coverage
Portable MRI has potential for MS
A blinded study showed good agreement with high-field MRI for some applications, but more development is needed.
Conference Coverage
A better MS measure?
A ‘digital carpet’ may provide more granular information about functional decline in patients with MS.
Conference Coverage
Cutting calories may benefit cognition in MS
For patients with MS, cognition can be positively influenced by healthy dietary habits.
Conference Coverage
High level of psychiatric morbidity in prodromal MS
The relative risk of psychiatric morbidity was up to 88% higher in patients with MS, compared with their counterparts without the disease.
Conference Coverage
MOGAD: Immunotherapy predicts fewer relapses
IVIG therapy appears to be the most effective for reducing relapses.
Conference Coverage
To prevent MS, should we target EBV?
Can a vaccine against EBV reduce MS incidence on a population level? Two experts debate.
Conference Coverage
Differential diagnosis in MS: What to watch for
‘Red flags’ suggest something other than MS.
Conference Coverage
CBT alone and with meds may decrease MS fatigue
“Clinicians should consider clinical characteristics and overall treatment goals when selecting fatigue interventions, to offer a more...
Conference Coverage
Early MS biomarkers may improve prediction of long-term outcomes
Combining two biomarkers may shed more light on MS prognosis.
Conference Coverage
B-cell depletion overkill?
B-cell depletion following ocrelizumab or rituximab treatment often lasts longer than 6 months.
Conference Coverage
Home cognitive therapy looks feasible in MS
A randomized trial demonstrates how to deliver therapy at home.
Conference Coverage
DMTs tied to lower MS relapse during reproductive therapy
The likelihood of achieving pregnancy through assisted reproductive technologies while having MS appeared favorable.